Tragically, the outbreak of Ebola that started in West Africa in 2014 has been far more extensive and damaging than any previous outbreaks. The duration of the outbreak has, for the first time, allowed the clinical evaluation of Ebola treat- ments. This article discusses the designs used for two such clinical trials which have recruited patients in Liberia and Sierra Leone. General principles are outlined for trial designs intended to be deployed quickly, adapt flexibly and provide results soon enough to influence the course of the current epidemic rather than just providing evidence for use should Ebola break out again. Lessons are drawn for the conduct of clinical research in future outbreaks of infectious diseases, where the sequence of events may or may not be similar to the West African Ebola epidemic.
Read full article here: https://www.ncbi.nlm.nih.gov/pubmed/26768556
- Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review
- Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients
- Clinical REsearch During Outbreaks (CREDO) Training for Low- and Middle-Income Countries
Please Sign in (or Register) to view further.